trending Market Intelligence /marketintelligence/en/news-insights/trending/k_VuLmfErGlJcKG3Zpwf5w2 content esgSubNav
In This List

Sapporo Clinical Laboratory fiscal Q2 profit falls YOY


Gold - Geopolitical tensions and inflation remain key drivers


Lithium and Cobalt - Softer demand weighs on prices


Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten


Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Sapporo Clinical Laboratory fiscal Q2 profit falls YOY

Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal second quarter ended Sept. 30 amounted to ¥42.22 per share, a decrease of 10.1% from ¥46.97 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥146.9 million, a decrease of 21.4% from ¥186.9 million in the year-earlier period.

The normalized profit margin declined to 3.4% from 4.5% in the year-earlier period.

Total revenue climbed on an annual basis to ¥4.29 billion from ¥4.17 billion, and total operating expenses climbed from the prior-year period to ¥4.06 billion from ¥3.88 billion.

Reported net income decreased 18.1% on an annual basis to ¥149.0 million, or ¥42.83 per share, from ¥182.0 million, or ¥45.74 per share.

As of Nov. 13, US$1 was equivalent to ¥122.78.